Last 27 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.85 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 11.71 | 2.91 | 359.27 | 120.40 | 239.23 | 606.31 | 314.22 | 606.44 | 533.99 | 157.05 | 78.46 | 41.94 | 85.46 |
| — | -99.5% | +14.3% | -80.1% | -55.2% | +286.1% | +300.5% | +1346.0% | +524.8% | +29.7% | -31.6% | -52.0% | +2.6% | |
| P/B Ratio | 1.05 | 0.98 | 5.96 | 28.23 | 3.09 | 2.87 | 2.62 | 3.77 | 3.58 | 2.68 | 1.37 | 0.91 | 1.42 |
| — | -66.0% | +127.1% | +648.9% | -13.7% | +7.2% | +90.8% | +312.6% | +152.7% | +38.5% | -37.5% | -60.3% | -26.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 11.00 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Atrium Therapeutics, Inc.'s operating margin was -88.0% in Q1 2026, up 5504.0 pp QoQ and up 8272.9 pp YoY. The trailing four-quarter average of -2910.5% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 99.2% | 100.0% | 100.0% | -3490.5% | 100.0% | 100.0% | 100.0% | 66.4% | 81.9% | 72.0% | -1593.2% | -1742.5% |
| — | -0.8% | 0.0% | 0.0% | -5356.2% | +22.1% | +39.0% | +106.3% | +103.8% | +104.0% | +104.7% | -13.5% | -0.9% | |
| Operating Margin | -412.6% | -88.0% | -5592.0% | -1513.5% | -4448.7% | -8360.9% | -4069.6% | -4200.9% | -4040.4% | -2178.6% | -3043.5% | -2080.4% | -2272.6% |
| — | +98.9% | -37.4% | +64.0% | -10.1% | -283.8% | -33.7% | -101.9% | -77.8% | +15.5% | -58.3% | -14.9% | -6.9% | |
| Net Margin | -411.9% | -84.7% | -5595.9% | -1398.3% | -4089.3% | -7360.0% | -3439.5% | -3441.7% | -3461.8% | -1943.4% | -2756.2% | -1858.0% | -2030.4% |
| — | +98.8% | -62.7% | +59.4% | -18.1% | -278.7% | -24.8% | -85.2% | -70.5% | +17.2% | -51.2% | -5.8% | +3.2% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -9.4% | -7.5% | -22.9% | -24.8% | -12.5% | -8.4% | -7.0% | -5.9% | -6.9% | -10.3% | -11.9% | -9.7% | -8.4% |
| — | +10.4% | -227.6% | -320.6% | -80.8% | +18.7% | +41.2% | +39.3% | +18.0% | -12.2% | -12.3% | +16.2% | +31.0% | |
| ROA | -8.3% | -5.8% | -17.3% | -21.2% | -11.1% | -7.7% | -6.4% | -5.4% | -6.2% | -8.7% | -10.1% | -8.8% | -7.7% |
| — | +23.9% | -171.0% | -293.8% | -80.6% | +12.1% | +36.6% | +39.2% | +19.8% | -4.2% | -6.6% | +13.6% | +29.2% | |
| ROIC | -10.0% | — | — | -31.4% | -12.6% | -8.6% | -7.7% | -8.2% | -12.1% | -16.7% | -13.0% | -10.3% | -9.1% |
| — | — | — | -283.2% | -4.1% | +48.4% | +40.8% | +20.0% | -32.8% | -34.9% | +19.5% | +23.0% | +33.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 22.9% YoY to 13.04x, tightening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.01 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 |
| — | +154.6% | +271.2% | +297.6% | -37.3% | -59.2% | -75.7% | -75.3% | -59.6% | -39.1% | +6.4% | -31.6% | -46.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.53 | 13.04 | 6.53 | 8.55 | 9.26 | 16.91 | 15.73 | 17.76 | 15.78 | 12.47 | 7.58 | 11.40 | 13.14 |
| — | -22.9% | -58.5% | -51.9% | -41.3% | +35.6% | +107.7% | +55.7% | +20.1% | +0.4% | -36.9% | +17.4% | +9.5% | |
| Quick Ratio | 6.53 | 13.04 | 6.53 | 8.55 | 9.26 | 16.91 | 15.73 | 17.76 | 15.78 | 12.47 | 7.58 | 11.40 | 13.14 |
| — | -22.9% | -58.5% | -51.9% | -41.3% | +35.6% | +107.7% | +55.7% | +20.1% | +0.4% | -36.9% | +17.4% | +9.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 27 years · Updated daily
Total return calculator · dividends reinvested
Calculate ReturnsDollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Compare NowQuick answers to the most common questions about buying RNA stock.
Atrium Therapeutics, Inc.'s current P/E is -2.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Atrium Therapeutics, Inc.'s current operating margin is -412.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Atrium Therapeutics, Inc.'s business trajectory between earnings reports.